Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 5/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MDM4 | O15151 | 1/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.36 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.36 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14801 | 0.84 | NPC1 (0.49) | KMT2AGAALMNAS1PR1MEN1 | |
| SCHEMBL18968497 | 0.80 | KMT2A (0.46) | KMT2AGAALMNAS1PR1RORC | |
| SCHEMBL27180693 | 0.69 | LMNA (0.65) | KMT2AGAALMNAS1PR1MEN1 | |
| SCHEMBL18516792 | 0.68 | NPC1 (0.69) | KMT2AGAALMNAMEN1ALDH1A1 | |
| SCHEMBL24747368 | 0.65 | LMNA (0.45) | KMT2ALMNAMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL21538241 | 0.59 | NPC1 (0.40) | KMT2ALMNARORCMEN1ALDH1A1 | |
| SCHEMBL18711334 | 0.59 | ALDH1A1 (0.75) | KMT2AGAAMEN1ALDH1A1MAPT | |
| SCHEMBL18711451 | 0.59 | KMT2A (0.77) | KMT2AGAALMNAMEN1RAB9A | |
| SCHEMBL5472405 | 0.58 | CNR2 (0.51) | KMT2ALMNAMEN1ESR1ALDH1A1 | |
| SCHEMBL9258208 | 0.58 | ESR1 (0.75) | S1PR1RAB9AESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9982309-B2 | Method for treating cell proliferation related disorders | AGIOS PHARMACEUTICALS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20170044620-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | SERVIER PHARMACEUTICALS LLC | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044620-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | IDH2, IDH1, IDH3B | KMT2A 457/4885GAA 1109/4885LMNA 1543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.